Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.34%
As of Wednesday, August 19, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.34%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Commentary & Analysis
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Down 9.51%
As of Friday, August 07, Verrica Pharmaceuticals Inc.’s VRCA share price has dipped by 9.51%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.36%
As of Monday, August 03, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.36%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 5.60%
As of Friday, July 31, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 5.60%, which has investors questioning if this is right time to sell.Michael Rose
Why Verrica Pharmaceuticals Inc.’s (VRCA) Stock Is Up 9.16%
As of Tuesday, July 28, Verrica Pharmaceuticals Inc.’s VRCA share price has surged by 9.16%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $83.5 | $618.0 | 20% |
|
| Shares Out (Mil) | 21.3 | 44.8 | 31% |
|
| Institutional Ownership | 44.7% | 85.3% | 19% |
|
| Float (Mil) | 7.9 | 47.4 | 17% |
|
| Beta | 1.49 | 0.70 | 83% |
|
| Avg Daily Volume (000s) | 91 | 390 | 34% |
|
| Price Change (52-week) |
(19.7%) | 68.6% | 30% |
|
| Growth | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 16.0% | (1.6%) | 66% |
|
| EPS (5yr) | 37.1% | 14.9% | 87 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (35.8%) | (14.9%) | 14% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.537) | ($2.007) | ($1.473) | |
| Month Ago EPS | ($0.427) | ($1.733) | ($1.243) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.445) | ($1.815) | ($1.430) | |
| Year/Year Chg | (13.4%) | 19.5% | (20.5%) | |
| Financials | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $30 | $291 | 16% |
|
| Net Income (TTM) (Mil) | ($31) | ($11) | 20% |
|
| EPS (TTM) | ($1.883) | ($0.700) | 15% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($6) | 18% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 16% |
|
| Enterprise Value (Q1) (Mil) | $71 | $450 | 19% |
|
| Valuation | VRCA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 19.44 | 2.78 | 95% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | VRCA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 37.7% | 67.0% | 46% |
|
| Net Margin | (102.8%) | (2.3%) | 7% |
|
| ROA | (83.0%) | (22.4%) | 7% |
|
| ROE | 473.3% | (20.2%) | 99% |
|
| Liabilities to Assets | 88.0% | 32.2% | 82% |
|
| F-Score | 6 | 3 | 67% |
|
Verrica Pharmaceuticals Inc. did not pass any screens on 8/20/2026.
